The OHSU Knight Cancer Institute, known as one of the pioneers in personalized cancer medicine, is an international leader in research and cancer treatment. The institute is the benefactor of $1 billion in philanthropic to overhaul early detection of lethal cancers and to recruit some of the world’s leading researchers. The Cancer Early Detection and Advanced Research (CEDAR) center within the Knight Cancer Institute as a result offers a unique opportunity for outstanding, driven and creative postdoctoral candidates to perform cutting edge and high-risk research ranging from understanding basic cancer biology to developing novel technologies to aid detection. To expedite the process of discovery, CEDAR offers generous internal funding mechanisms open to researchers at all stages of their career.
As part of this fellowship a successful candidate will have the opportunity to work with researchers in the CEDAR program, led by Dr. Sadik Esener, and researchers in the Precision Oncology Program, led by Dr. Gordon Mills. CEDAR is focused on detecting and treating lethal cancers at the earliest stage and the Precision Oncology Program is focused on obtaining a deep understanding of patient tumors to identify effective therapy for cancer patients.
Candidates will work closely with Prof. Gordon Mills, Dr. Hisham Mohammed and other CEDAR researchers to develop key questions on cancer initiation or develop novel single-cell and proteomics tools relevant to early detection and precision oncology.
We are hiring 1-2 highly motivated Postdoctoral Fellows to address the following general themes
- Develop existing or novel technologies with the aim of accurately monitoring biological processes at a single-cell proteomic, transcriptomic and epigenetic level. The team has previously developed proteomics (RIME, RPPA), single-cell and multi-omic technologies (Mohammed et al, Argelaut et al). Of particular interest is integrating tumor spatial information with single-cell transcriptomics, epigenetics (methylation, chromatin accessibility) and proteomics. This position will leverage unique partnerships with industry innovators.
- Investigate fundamental biological processes of cancer initiation and progression. Current interests include deciphering the role of hormone receptors (Mohammed et al, Nature 2018) and deep spatially oriented proteomic analysis of patient tumors to determine therapeutic opportunities. CEDAR researchers have unique access to longitudinal clinical samples and trials to test emerging hypotheses.
- Computational biologists with an interest in driving single-cell and multi-omic projects in clinical settings are also encouraged to apply. The position may also involve developing new computational methods and deep learning tools to complement novel technologies developed in the lab.
- Mohammed, H. et al. Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor. Cell Reports 3, 342-349 (2013).
- Mohammed, H. et al. Progesterone receptor modulates ER? action in breast cancer. Nature 523, 313-317 (2015).
- Heiser, L. M., Mills, G. B. & Gray, J. W. Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. Cancer Cell 35, 341-343 (2019).
- Clark, S. J. et al. scNMT-seq enables joint profiling of chromatin accessibility DNA methylation and transcription in single cells. Nature Communications 9, 390 (2018).
- Lee, J. et al. Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. Molecular & Cellular Proteomics 17, 1245-1258 (2018).
How to Apply